Back buttonBack

Welcome to PEMAZYRE® Switzerland

This website is intended for healthcare professionals located in Switzerland

Please login:

Swiss Professional Information Swiss Patient Information
orange diamonds

What's on this site:

DNA helix

Mechanism of action

Histogram and magnifying glass

Efficacy

Shield and tick

Safety profile

Clock and pill

Dosing and administration schedule

Targeted medicine

FGFR2 fusion
testing

PEMAZYRE eDetail

Cholangiocarcinoma (CCA) & PEMAZYRE self-directed learning

A self-directed learning material to complete in your own time. With the learning module you can learn about the unmet needs in CCA, discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.
orange diamonds
Medical book

FGFR2 fusion testing

Discover about FGFR2 fusions in patients with CCA.

Incyteful Platform

Incyteful for you

An Incyte platform that offers medical education relevant to your daily practice. Easy to access, personalised content that fits with your schedule.

Incyteful is your one-stop resource for updates about the disease areas and Incyte's approved products that you care about.

Coming soon

External link disclaimer

Intended for licensed healthcare professionals located in Switzerland.

You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third⁠–⁠party sites. Would you like to continue?

Yes No

Report an adverse event

Terms of Use Privacy Policy Cookie Policy
Report an adverse event Swiss Professional Information Swiss Patient Information

IMPRESSUM
This website was created by Incyte

Incyte Biosciences International Sàrl
Rue Dr Yersin 12
CH-1110 Morges
Switzerland

Oncology.CH@incyte.com
+41 21 581 50 00

Marketing authorisation holder:
Incyte Biosciences International Sàrl, Morges

Healthcare professionals are required to report any suspected new or serious side effects. See the “Undesirable effects” section of the Swiss Professional Information for the terms and conditions for reporting side effects.

Adverse events should also be reported to Incyte immediately by phoning 00800 000 274 23 or via email at eumedinfo@incyte.com.

CH/PEMA/P/24/0002
Date of preparation: April 2024
This website is created and funded by Incyte
© 2024, Incyte. All rights reserved.
PEMAZYRE, the PEMAZYRE logo and the Incyte logo are registered trademarks of Incyte

If you would like to request further medical information, please visit:
https://www.incyteglobalmedicalinformation.com/

External link disclaimer

Intended for licensed healthcare professionals located in Switzerland.

You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third⁠–⁠party sites. Would you like to continue?

Yes No

Report an adverse event